Delivering the highest quality cannabidiol (CBD) products under the brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil & More.
August 27, 2021
Can B Corp. (OTCQB: CANB) is a health and wellness company that specializes in CBD brands and utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. The Company recently launched Can B SuperFoods, a line of nutritional supplements, and they are a license holder of the LifeGuard® Brand, which is developing a line of consumer products. Can B also owns and operates an R&D and production facility in Lacey, WA, and Green Grow Farms, a licensed hemp growing and cultivation site in New York.
Who is Can B?
The Growing Demand for CBD
What was once whispered about in stoner’s garages and holistic wellness circles, is now a household name. That name: cannabidiol, or specifically, CBD.
In 2020, the global CBD market was valued at USD 2.8 billion and it’s expected to grow at a compound annual growth rate (CAGR) of 21.2% from 2021 to 2028. Some research groups even estimate a market growth rate as high as 31.9% between 2020 and 2027.
Because CBD doesn’t have intoxicating or psychoactive effects, it’s been accepted in therapeutic, cosmetic, and medical industries as a natural treatment for a variety of ailments. As more states legalize the use of marijuana, and THC, the cannabidiol aspect of the cannabis plant becomes even more popular.
As government approvals and public opinion continue to support the CBD market’s extensive growth, more commercial retailers are offering CBD and hemp-derived products. In addition, the B2B segment flourished as the need for Wholesale CBD and CBD as a raw material expanded.
Most recently, the pharmaceutical industry dominated the CBD market, as the amount of trials and studies involving CBD continues to go up. According to Grand View Research, “The pharmaceutical segment is projected to witness the fastest growth rate over the forecast period. This rapidly progressing transformation of cannabidiol from herbal preparations to prescription drugs is anticipated to boost the growth of the market. Furthermore, growing awareness about the medical benefits of cannabidiol, including its healing properties, is anticipated to drive the product demand in the pharmaceutical industry.”
Can B’s brands, Canbiola, and, Pure Health Products, offer wholesale CBD or formulas for use in pharmaceutical and medical industries. Not to mention they have several consumer focused brands and products, truly covering all aspects of CBD sale, and taking advantage of all growth avenues.
Can Can B be your Next Investment?
A snapshot of why Can B Corp is a sound investment:
Actual 3-year revenue CAGR 1800%
Vertically integrated, seed-to-sale business
Partnerships with brands such as LifeGuard®
Medical device division capitalizes on accompanying market segment
Addressing a $2.8 billion industry
Partnerships and Acquisitions
Coming off the back of a strong Q1 2021, Can B is primed for growth. As the markets continue to tend positively for all things CBD and Hemp, it becomes a question of breaking through the noise while providing excellent products at scale.
We like that Can B is taking such a unique angle with their branding, using stuntmen and action athletes to promote the existing CBD products: CryoGel Gold 500 mg and Salve 100 & 200 mg. This is an unexplored niche, completely open for establishing a strong brand relationship with a new consumer base. Additionally, Can B will be launching an entirely new line of products in Sept of 2021 to further this effort.
“This is a really exciting new partnership for (Can B), as it provides a new untapped distribution channel for our manufacturing and production, which remains under-utilized. Our Lacey, Washington facility continues to have an excess capacity which we can use for new private label customers. This group of Professional Hollywood Stuntmen and World Champion Action Sports Athletes has great exposure and a wide social media following, which they will utilize to market and advertise the CBD products.” said Marco Alfonsi, Can B’s Chief Executive Officer.
Can B plans on using social media influencers and other media opportunities to make the most out of this specific partnership, leaning on the strength of their new partners’ followings to help boost awareness and sales.
But high-flying wire stunts and extreme athletics aren’t the only things that have us excited about Can B this year. We have an eye on the recent acquisition of assets from TWS Pharma and Music City Botanicals, moves that will enhance Can B’s ability to produce hemp and extract the valuable oils at scale.
Marco Alfonsi, Can B’s Chief Executive Officer, commented, “This is a significant move for our Company that we strongly believe will add value for our shareholders. It enables us to process biomass into isolate which is the core ingredient for hemp isomers, such as CBN, CBG, Delta-8 and Delta-10. It is strategic to our existing Lacey, Washington facility and expected to add significantly to revenue from now through the end of 2021. By securing our own processing and extraction facilities we for the first time control our supply chain from biomass through end products for both retail and wholesale customers”. He added in a separate release, “This acquisition brings us additional complementary assets that enable us to control our supply chain from biomass through end products for both retail and wholesale customers. Our previously announced acquisition of TWS Pharma assets will feed this isomer operation and provide us cost synergies and scale. CAN B is now a full-service hemp-derived cannabinoid company that can facilitate servicing the large box types as well as the boutique vape and smoke store”
The increased control over the supply chain boosts the quality of the end product, while also reducing the costs associated with obtaining usable isolate. With these recent acquisitions, Can B is right on track to become one of the biggest players in their space.
Closing Out a Strong Q2 2021
Key Financial and Business Highlights during and subsequent to Q2 2021:
Revenue increased 96% over Q2 2020 to $0.4 million for Q2 2021
Adjusted EBITDA loss of $2.1 million (for the 1st half of 2021)
Partnered with group of professional Hollywood stuntmen and world champion action sports athletes for CBD products.
Purchased additional equipment to increase production at its hemp facility in Colorado
Marco Alfonsi, Can B’s Chief Executive Officer, stated, “We witnessed a nice uptick in business during the quarter as elective surgeries resumed and our medical durable equipment segment benefited. Our business pipeline remains strong for both our own branded lines and our private label contract manufacturing. Additionally, our high activity of strategic corporate discussions and negotiations have led to meaningful opportunities such as the TWS Pharma asset acquisition announced via an 8K filing on August 17, 2021, adding over $5 million in assets to our balance sheet. Opportunities like these we believe will accelerate our growth and further solidify our balance sheet.”
Financial Results for the Three Months Ended June 30, 2021:
Revenue: For the three months ended June 30, 2021, revenue was $0.4 million, an increase of $0.2 million, or 96%, compared with $0.2 million for the three months ended June 30, 2020. This increase was primarily due to the resumption of elective surgeries in 2021 which were temporarily paused through Q2 of 2020 due to the impact of the Covid-19 outbreak. Medical durable equipment utilized in elective surgeries is the Company’s primary medical device revenue. In addition, the increase was related to operations of the Company’s delta-8 synthesizing business which began in March 2021.
Gross Profit: For the three months ended June 30, 2021, gross profit was $0.1 million, a decrease of $0.1 million, or 9%, compared with $0.2 million for the three months ended June 30, 2020. The resulting gross margin was 35.6%, compared with 76.6% for the same quarter last year. The decrease in gross margin is due to an increase in medical durable equipment contribution to revenue and an increase in inventory pricing.
Total Operating Expenses: For the three months ended June 30, 2021, total operating expenses were $2.7 million, an increase of $1.5 million, or 115%, compared with $1.3 million for the same quarter last year. The increase in operating expenses was primarily due to professional fees incurred and attributable to the Company’s asset acquisitions and Regulation A offering.
Operating Loss: For the three months ended June 30, 2021, operating loss was $0.6 million, an improvement of $0.2 million, compared with an operating loss of $0.8 million for the same quarter last year.
Net Loss: For the three months ended June 30, 2021, net loss was $2.8 million, or ($0.12) per share, compared with a net loss of $1.2 million, or a net loss of ($0.33) per share, for the three months ended June 30, 2020.
Cash: Cash and cash equivalents totaled $1.1 million as of June 30, 2021.
Financial Results for the Six Months Ended June 30, 2021:
Revenue: For the six months ended June 30, 2021, revenue was $0.7 million, a decrease of $0.1 million, or 9%, compared with $0.8 million for the same period last year. The Company began to rebound and increase revenues compared to prior periods in Q2 of 2021 due to the resumption and surge of elective surgeries in Q2 2021. In addition, certain distributors lost clients due to business closings which had an additional impact on the Company’s overall revenue activity.
Gross Profit: For the six months ended June 30, 2021, gross profit was $0.4 million, a decrease of $0.2 million, or 38%, compared with $0.6 million for the same period last year. The resulting gross margin was 52.7%, compared with 78.1% for the same period last year.
Total Operating Expenses: For the six months ended June 30, 2021, total operating expenses were $4.8 million, an increase of $1.9 million, compared with $2.8 million for the same period last year.
Of note, $2.8 million of the Company’s operating expenses for the six months ended June 30, 2021, were non-cash expenses, including depreciation, amortization, and stock-based compensation.
Operating Loss: For the six months ended June 30, 2021, operating loss was $4.4 million, an increase of $2.2 million, compared with an operating loss of $2.2 million for the same period last year.
Net Loss: For the six months ended June 30, 2021, net loss was $4.9 million, or ($0.26) per share, compared with $2.4 million, or ($0.65) per share, for the same period last year.
CANNABIDIOL: the Relationship between CBD Oil and the Immune System – ScHO Keynote by Dr. Kornfeld
The 411 on CBD
The CBD industry isn’t just growing, it’s booming. Despite the COVID-19 pandemic, the demand for CBD oil and products has increased exponentially. Whether the quarantine has negatively affected people’s mental health or just made them more health conscious, it seems that the population has come to tout its benefits.
CBD has been shown to successfully reduce stress and anxiety in adults, and even pets! Traditional treatments for anxiety, depression and other mental illnesses typically involve benzodiazepines or other drugs with potentially harmful side effects. All types of “benzos” work in similar ways in regards to how they affect GABA receptors in the brain. These GABA receptors outnumber the brain’s neurotransmitters and tend to make neurons less excitable, i.e. they help calm your brain down.
Benzos latch onto these GABA receptors and make it easier for them to enter cells, producing a quick calming effect. This may help reduce anxiety and bring on sleep, but these results are temporary. Because benzos quickly increase GABA receptor activity the brain augments the natural process of GABA receptors in order to maintain balance. Meaning, that the longer and more often you take benzos, the more you’re going to need. You’ve built up a tolerance to it now and are more likely to become addicted. Not to mention that if you quit cold turkey, you’ll go through painful withdrawal symptoms.
CBD is a natural alternative and has been found to have a favorable safety profile. Cannabidiol is a compound found in the cannabis plant, but unlike its plant sister, THC, CBD doesn’t have intoxicating effects. In addition to being used for anxiety, depression and other mental illness treatment, CBD is also an anti-inflammatory, making it a great addition to skincare products.
Cannabidiol has been known to treat skin conditions such as redness, inflammation, dryness and radical damage. It holds serious antioxidant and anti-inflammatory benefits, making it good for fighting mild to severe skin irritation. Can B’s spa line, Seven Chakras, and their multi-faceted, Pure Leaf Oil brand, carries a number of lotions, oils and isolates to help your skin and body.
While the pandemic has been devastating in so many ways, one bright spot is that most people are taking longer looks at self-care and their overall wellbeing, meaning CBD and other natural products that help physical and mental health, are on the rise.
The global CBD market is expected to grow at a CAGR of at least 21.2% from 2021 to 2028. CBD companies that control as many aspects of the process as possible are the ones most situated to experience growth, as more and more sales are coming from the medical and pharmaceutical industries that need CBD in various different formats. Can B not only owns the cannabis farms; they own formulas, wholesale products, and retail products. With the CBD industry on the rise, this vertically integrated and multi-channel company is uniquely positioned to reap the benefits.
Chairman & Chief Executive Officer
Marco Alfonsi has been a financial service professional for over 20 years. Throughout his career, Mr. Alfonsi was directly and indirectly involved in raising over $100 million dollars for small and medium sized business. Prior to his involvement in the financial services industry, Mr. Alfonsi has owned, operated, financed and sold several businesses. Mr. Alfonsi successfully started and managed two companies (ExecuteDirect.com, and Bakers Express of New York, Inc.), and held senior management positions with a number of financial institutions including Global American Investments, Clark Street Capital, and Basic Investors.
Stanley L. Teeple
Director & Chief Financial Officer
Mr. Teeple was engaged from 2017-2018 with Solis Tek, Inc. (OTCQB:SLTK) a California based publicly traded corporation as Senior Vice President, Corporate Secretary , and Chief Compliance Officer. Solis Tek, Inc. a NV Corporation, is a developer of lighting and nutrient products, and most recently in cultivation and processing for the cannabis industry. Previously, from 2015-2016 Mr. Teeple was Chief Financial Officer and Secretary for Zonzia Media, Inc. (OTC:ZONX), a provider of streaming video and content to cable subscribers and hotel networks throughout the eastern US. From 2008 to 2014 Mr. Teeple was Chief Financial Officer and Secretary of Indigo-Energy, Inc. (OTC:IDGG) a publicly traded company in the oil and gas exploration business. Over the prior three plus decades Mr. Teeple through his turnaround consulting business, Stan Teeple, Inc., has held numerous senior management positions in several public and private companies across a broad spectrum of industries. Additionally he has operated and worked for various court appointed trustees and principals as CEO, COO, and CFO in the entertainment, pharmaceuticals, food, travel, and tech industries. He operated his consulting business on a project-to-project basis and holds various other directorships. His businesses operational strengths include knowing how to manage and maximize the resources and preserve the integrity of a company from start-up through to maturity and corporate compliance in a regulatory environment.
Philip P. Scala
Chief Operating Officer
Mr. Scala has acted as founder and CEO of Pathfinder Consultants International, Inc. (“Pathfinder”) since 2008. Pathfinder offers unique expertise and delivers the information you need to make informed decisions, whether in times of crisis or in the course of simply running your business. Prior to forming Pathfinder, Mr. Scala served the United States both as a Commissioned Officer in the US Army for five years followed by his 29 years of service with the FBI. Mr. Scala received his bachelor’s degree and Master of Business Administration in accounting from St. John’s University, he also earned a Master of Arts degree in Psychology from New York University.
Pure Leaf Oil, Chief Operating Officer
As the Chief Operations Officer of Can B Corp, David will expand the company’s product lines across the board, engage market leaders and produce first-to-market products for CBD industry worldwide. David Posel started his earliest years as a metallurgical engineer at AGCO Metalex, a large precious metals refinery in Washington State. The son of a Ph.D. chemist, Boeing engineer and mathematics major, he quickly went on to the Semiconductor manufacturing industry for nearly a decade as a metallic silicon coatings engineer, leaving to attend ASU West in Arizona. With an engineering and metallurgical chemistry background, David switched gears to Organic agricultural production for an additional eight years. David was farm director and chief environmental scientist for what was once the oldest Organic farm in the state of Colorado before moving into the more advanced world of CBD, hemp production, and custom product development. David has spent years earning the respect of CBD market leaders and forming solid business relationships both in the US and abroad. His career began by making the first CBD infused consumer product offered in the US with 99% isolate, ‘CrystalPure CBD’ which is now sold under the Canbiola brand.
Who are we and what do we do?
We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”).
How is the Information published?
We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us.
Our publication of the Information is known as a “Campaign”.
Will everyone receive the Information at the same time?
No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart.
How is a potential investor impacted if he receives the Information later than other investors?
Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer increased trading losses if he purchases the securities of a Profiled Issuer.
What will happen to the shares that we hold during the Campaign?
We will sell the shares we hold while we tell investors to purchase during the Campaign.
What will happen when the Campaign ends?
Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment.
Why do we publish only favorable Information?
We only publish favorable information because we are compensated to publish only favorable information.
Why don’t we publish negative Information?
We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information.
Is the Information complete, accurate, truthful or reliable?
No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable.
What we do not do?
We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.
Where does the Information come from?
The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources.
If we say we make “stock picks,” are those picks our own?
No, they are not. We are compensated to advertise the securities we are told to advertise.
What will happen if an investor relies on the Information?
If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.
Who pays us to publish the Information?
The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.
The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”.
What warranties do we make about the Information?
None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.
What we are not.
We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
An independent adviser or consultant;
A fortune teller;
An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
A broker-dealer or an individual acting in the capacity of a registered representative or broker;
A stock picker;
A securities trading expert;
A securities researcher or analyst;
A financial planner or one who engages in financial planning;
A provider of stock recommendations;
A provider of advice about buy, sell or hold recommendations as to specific securities; or
An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of?
No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.
What conflicts of interest do we have in publishing the Information?
We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
What will happen to the shares that we hold during the Campaign?
We will sell the shares we hold while we tell investors to purchase.
Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
We do not publish any negative information whatsoever about the Profiled Issuers;
We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
A short time after we acquire a Profiled Issuer’s securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information?
The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information.
What do we urge potential investors to do?
We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.
Why is this Disclaimer being provided?
We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares.
The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.What are other risks that investors should be aware of?
Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.
If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.govwww.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.
What we were paid to advertise the Profiled Issuers.
The details of our compensation and the period of the Campaign is set forth below.
Name of Issuer & Ticker Symbol - Can B Corp. (CANB)
Amount & Form of Compensation - $148,000 in Common Stock
Who Paid for the Campaign & Position with Company if any - Can B Corp. (CANB)
Period of Campaign - 06/09/2020 - 02/01/2022
What securities of the Profiled Issuers do we hold?
The positions we hold of the Profiled Issuer are set forth below. We plan to sell these securities during the Campaign.
Name of Issuer & Ticker Symbol - Can B Corp. (CANB)
Number of Shares We or our Affiliates Hold - 185,000
. To find out more, read our